We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
1x
Chapters
descriptions off, selected
captions and subtitles off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
In this video, Daniel DeAngelo, MD, PhD, discusses the results of a study presented at ASH Annual Meeting 2024 that examined the use of menin inhibitors in patients with leukemia.
DeAngelo, chief of the division of leukemia at Dana-Farber Cancer Institute, highlighted a phase 2 study of revumenib (Revuforj, Syndax Pharmaceuticals) in patients with relapsed or refractory KMT2A acute leukemia.
“These are really exciting results with single-agent therapy. It represents a new field that’s being developed with lots of players — not just revumenib, but also other menin inhibitors now are in development,” DeAngelo said.
Reference:
Aldoss I, et al. Abstract 211. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.
